The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•9 June 2026•

2 min read

RedHill's Opaganib Gains FDA Rare Pediatric Disease Designation for Neuroblastoma

Key Facts

1The U.S. FDA granted rare pediatric disease designation to opaganib for the treatment of neuroblastoma.

2The designation provides for a potential Priority Review Voucher (PRV), application fee waivers, and seven years of marketing exclusivity.

3The neuroblastoma market is projected to be valued at approximately $3.5 billion by 2032.

In a move that strengthens the outlook for innovative oncology treatments, the U.S. FDA has granted rare pediatric disease designation to opaganib for the treatment of neuroblastoma. According to reports, this designation provides the company with potential eligibility for a Priority Review Voucher (PRV) along with benefits such as application fee waivers and seven years of marketing exclusivity. The neuroblastoma treatment market is projected to reach a valuation of approximately $3.5 billion by 2032.

This regulatory milestone follows positive preclinical data presented at the 2026 AACR Annual Meeting, which demonstrated the drug's potential as an add-on therapy. Compared to other micro-cap biotech peers, securing a PRV is a significant strategic asset; similar vouchers have commanded secondary market prices between $100 million and $110 million in recent years per industry data. This marks the second major designation for opaganib following its previous Orphan Drug status.

Investors should monitor the timeline for upcoming clinical trials as a primary catalyst, as final approval remains contingent on late-stage results. Looking at the economic calendar, the market is awaiting the OPEC Meeting on June 7, 2026, which may influence broader risk sentiment. In the absence of current instrument price data in the pre-fetched database, focus remains on the company's ability to monetize these new regulatory advantages.